 |
|
Late-Onset Myasthenia Gravis
A Changing Scene
Johan A. Aarli, MD
Arch Neurol. 1999;56:25-27.
ABSTRACT
The prevalence of myasthenia gravis (MG) among middle-aged and older patients has increased. Patients with early-onset MG live longer than before, but there is also an increase in late-onset MG (onset of the disease after the age of 50 years in patients with no clinical or paraclinical evidence of a thymoma). Epidemiological data support using the age of 50 years to separate early- and late-onset MG. The main immunological difference between early- and late-onset MG is the presence of antibodies to muscle titin, which are detected in approximately 50% of patients with late-onset MG. Treatment of late-onset MG has to be tailored both to the age of the patient and to the immunological findings of that particular form of MG.
|
The disease occurs, for the most part, in the third decade, and is rare before the age of 15, or after 70. In approximately 60 per cent of the patients the disease develops between the ages of 20 and 40.1
The concept that myasthenia gravis (MG) mainly affects young adults and is uncommon after the age of 50 years was based on clinical experience and supported by epidemiological data. In 1900, when Campbell and Bramwell2 surveyed the literature and added 1 case of their own, they identified 60 cases, 3 of which involved patients who were older than 50 years at the onset of their disease. By 1953, Schwab and Leland3 reported that 62% of women and 27% of men with MG were younger than 30 years at the onset of the disease. The corresponding figures reported by Simpson et al4 in 1966 were 49% women and 23% men. In both studies, the disease was uncommon among younger men, with the majority of male patients being older than 60 years. Men with MG formed 2 groups: one with the peak age at onset between 25 and 35 years and the other between 60 and 70 years.4 These observations were reflected in standard textbooks of neurology.
Today, some 40 years later, the onset of MG occurring after the age of 50 years is not uncommon. Recent studies have shown an increased prevalence of the disease among middle-aged and older patients.5-8 This may be the result of both an improved prognosis and a more advanced medical diagnosis among elderly patients. Certainly, most patients with MG receive better treatment today and have a longer life span than ever before. However, the data suggesting a higher prevalence of MG cannot be explained by an accumulation of patients with early onset of the disease who live longer, although in the 1990s the life expectancy of patients with early-onset MG who have undergone a thymectomy does not differ from that of the normal population.9
There are also a substantial number of patients who develop the disease much later in life. Three recent studies, from western Denmark,5 central and western Virginia in the United States,6-7 and Croydon, Great Britain,8 have demonstrated an increased incidence of MG in the elderly population. In a Dutch study of 100 consecutive patients with MG who were referred between 1985 and 1989, 33% were older than 50 years at the onset of the disease.10 In an epidemiological study from central and western Virginia, the prevalence was significantly higher in individuals older than 50 years.6 Moreover, when prevalence rates were analyzed, the figures for MG showed an increase over time, compared with rheumatoid arthritis and systemic lupus erythematosus, for which trends were static.11
Myasthenia gravis has traditionally been regarded as a disorder of young women and older men. The incidence of MG is still higher among younger women than it is among young men, but recent studies have demonstrated that both sexes now show a bimodal curve for age at onset of MG.5, 12-13 The age peak for late-onset MG (onset after the age of 50 years) is now the same for both sexes, between 70 and 80 years, mainly because of a relative increase in the disease among older women.14 Using linear regression techniques, Phillips15 has calculated that 61.3% of all patients with MG in the United States are now older than 50 years.
The age structure of the population of western societies is changing. Thirty-two percent of the population in the countries of the European Union are older than 50 years.16 A similar aging process is taking place in the population of the United States.17 An expansion of the age group from which late-onset MG is recruited will in itself lead to an increase in the number of patients. Neurologists will therefore see more patients with late-onset MG than ever before.
When does late-onset MG start? Compston et al,18 in their 1980 study, suggested 40 years of age as an arbitrary division. Somnier et al14 have pointed out that incidence data are more in favor of separating early- and late-onset MG at the age of 50 years. Late-onset MG is defined herein as the onset of the disease after the age of 50 years in a patient with no clinical or paraclinical evidence of a thymoma but, quite often, with immunological findings similar to those found in patients with thymoma.19
Is late-onset MG different from early-onset MG? Yes, in many respects. Thymoma is much more common among middle-aged and older patients. But, even late-onset, nonthymoma MG has characteristics that differentiate it from early-onset disease. Patients with early-onset MG are often DR3 positive and show a high frequency of clinical and serological autoimmune overlap. Patients with thymoma-associated MG are never, or almost never, DR3 positive, and this haplotype is also uncommon in late-onset MG.19 It has therefore been postulated that late-onset MG is a disease that is different from early-onset MG.14, 18
The neuromuscular symptoms seen in patients with late-onset MG do not differ from those observed in patients with early-onset MG, although the disease is more likely to be more severe in patients in whom MG develops after the age of 50 years.20 It has been known for a long time that MG with thymoma has a poorer prognosis than MG without thymoma. The difference in prognosis is probably not related to the size of the tumor, since patients with small thymomas may also have a more serious prognosis. Somnier21 therefore postulated that the severity of the disease is related to immunological factors associated with the thymoma. In his study, removal of a thymoma in MG resulted in an exacerbation of the clinical severity of the disease and an increase in acetylcholine receptor antibody titers.
The majority of patients with MG, whether it be of early or late onset, have circulating antibodies to the acetylcholine receptor, but the concentration is often lower in those with late-onset disease.22-23 The main immunological difference between early- and late-onset MG is the presence of antibodies to striated muscle antigens, particularly antibodies to titin. These antibodies are found in serum samples from 85% of patients with MG with thymoma and from approximately 50% of those with late-onset MG, but are extremely rare in samples from those with early-onset MG (MG with thymus hyperplasia).19 The presence of these antibodies is not attributable to disease duration, since there is no relationship between titer and duration of the disease.24 Nor are they simply a phenomenon of aging, since they are not detected among healthy older individuals. Patients with late-onset MG with thymus involution who have striated muscle antibodies are immunologically identical to patients with MG with thymoma.19 These antibodies are mainly antibodies to titin.25-26 Disease severity in late-onset nonthymoma MG relates to the presence or absence of antibodies to the titin epitope MGT30. While not related to titer, there is a qualitative association of severity to titin antibodies.27 Some patients in whom the disease has developed late in life and who do not have titin antibodies may therefore represent a delayed early onset.
Somnier and Trojaburg28 reported that myopathy is more common in patients with late-onset MG than in those with early-onset MG. They also found that the occurrence of myopathy was associated with the presence of anti–striated muscle (titin) antibodies. Based on their observations, they suggested that the increased weakness seen in some older patients is caused by an immunologically mediated myopathy and that this could to some extent account for the poorer prognosis in patients with late-onset MG.
Treatment of late-onset MG can be difficult. The effect of acetylcholinesterase inhibitors is often temporary. Plasma exchange has more complications in the elderly. Keynes,29 one of the pioneers of surgical treatment of MG, observed that the results of thymectomy were much poorer in the older age group. He also pointed out, and others have confirmed, that patients with thymoma have a worse prognosis.21, 29 When thymoma cases are excluded, however, the age at onset may not significantly affect the response to thymectomy.30-31 It is known that some patients with late-onset MG do not improve after thymectomy and that a poorer outcome can be expected if myopathic deterioration already exists. Older patients are especially vulnerable to the many complications of long-term steroid therapy. The choice of immunosuppressive drugs may not be the same as in younger patients. The therapeutic situation in a case of late-onset MG is therefore different from that in a case of early-onset MG, and the treatment offered will have to be tailored both to the age of the patient and to the immunological findings of that particular form of MG.
AUTHOR INFORMATION
Accepted for publication March 13, 1998.
Reprints: Johan A. Aarli, MD, Department of Neurology, Haukeland Hospital, 5021 Bergen, Norway.
From the Department of Neurology, University of Bergen, Bergen, Norway.
REFERENCES
| |
1. Aird RB. Muscular atrophies and dystrophies. In: Baker AB, ed. Clinical Neurology. Vol 3. New York, NY: Hoeber & Harper; 1955:1498-1562.
2. Campbell H, Bramwell E. Myasthenia gravis. Brain. 1900;23:277-336.
FREE FULL TEXT
3. Schwab RS, Leland CC. Sex and age in myasthenia gravis as critical factors in incidence and remission. JAMA. 1953;153:1270-1273.
ISI
4. Simpson JF, Westerberg MR, Magee KR. Myasthenia gravis: an analysis of 295 cases. Acta Neurol Scand. 1966;42(suppl 23):1-27.
5. Christensen PB, Jensen TS, Tsiropoulos I, et al. Incidence and prevalence of myasthenia gravis in western Denmark: 1975 to 1989. Neurology. 1993;43:1779-1783.
FREE FULL TEXT
6. Phillips LH, Torner JC, Anderson MS, Cox CG. The epidemiology of myasthenia gravis in central and western Virginia. Neurology. 1992;42:1888-1893.
FREE FULL TEXT
7. Phillips LH, Torner JC. Epidemiologic evidence for a changing natural history of myasthenia gravis. Neurology. 1996;47:1233-1238.
FREE FULL TEXT
8. Schon F, Drayson M, Thompson RA. Myasthenia gravis and elderly people. Age Ageing. 1996;25:56-58.
FREE FULL TEXT
9. Christensen PB, Jensen TS, Tsiropoulos I, et al. Mortality and survival in myasthenia gravis: a Danish population based study. J Neurol Neurosurg Psychiatry. 1998;64:78-83.
FREE FULL TEXT
10. Beekman R, Kuks JBM, Oosterhuis HJGH. Myasthenia gravis: diagnosis and follow-up of 100 consecutive patients. J Neurol. 1997;244:112-118.
FULL TEXT
|
ISI
| PUBMED
11. Jacobson DL, Gange SJ, Rose NR, Graham NMH. Epidemiology and estimated population burden of selected autoimmune diseases in the United States. Clin Immunol Immunopathol. 1997;84:223-243.
FULL TEXT
|
ISI
| PUBMED
12. Storm-Mathisen A. Epidemiology of myasthenia gravis in Norway. Acta Neurol Scand. 1984;70:274-284.
ISI
| PUBMED
13. Osterman P. Current treatment of myasthenia gravis. Prog Brain Res. 1990;84:151-161.
ISI
| PUBMED
14. Somnier FE, Keiding N, Paulson OB. Epidemiology of myasthenia gravis in Denmark: a longitudinal and comprehensive population survey. Arch Neurol. 1991;48:733-739.
FREE FULL TEXT
15. Phillips II LH. The epidemiology of myasthenia gravis. Neurol Clin North Am. 1994;12:263-271.
16. Walker A, Maltby T. Ageing Europe. Philadelphia, Pa: Open University Press; 1997.
17. Katzman R. The aging brain: limitations in our knowledge and future approaches. Arch Neurol. 1997;54:1201-1205.
FREE FULL TEXT
18. Compston DAS, Vincent A, Newsom-Davis J, Batchelor JR. Clinical, pathological, HLA-antigen and immunological evidence for disease heterogeneity in myasthenia gravis. Brain. 1980;103:579-601.
FREE FULL TEXT
19. Aarli JA. Late onset myasthenia gravis. Eur J Neurol. 1997;4:203-209.
20. Donaldson DH, Ansher M, Horan S, Rutherford RB, Ringel SP. The relationship of age to outcome in myasthenia gravis. Neurology. 1990;40:786-790.
FREE FULL TEXT
21. Somnier FE. Exacerbation of myasthenia gravis after removal of thymomas. Acta Neurol Scand. 1994;90:56-66.
ISI
| PUBMED
22. Newsom-Davis J, Vincent A, Willcox N. Acetylcholine receptor antibody: clinical and experimental aspects. In: Receptors, Antibodies and Disease: Ciba Foundation Symposium 90. London, England: Pitman Books Ltd; 1982:225-247.
23. Limburg PC, The TH, Hummel-Tappel E, Oosterhuis HJGH. Anti-acetylcholine receptor antibodies in myasthenia gravis, I: relation to clinical parameters in 250 patients. J Neurol Sci. 1983;58:357-370.
FULL TEXT
|
ISI
| PUBMED
24. Kuks JBM. The Thymus and Myasthenia Gravis. Groningen, the Netherlands, Drukkerij Regenboog; 1992.
25. Aarli JA, Stefansson K, Marton LSG, Wollmann RL. Patients with myasthenia gravis and thymoma have in their sera IgG autoantibodies against titin. Clin Exp Immunol. 1990;82:284-288.
ISI
| PUBMED
26. Williams CL, Hay JE, Huiatt TW, Lennon VA. Paraneoplastic IgG striational autoantibodies produced by clonal thymic B-cells and in serum of patients with myasthenia gravis and thymoma react with titin. Lab Invest. 1992;66:331-336.
ISI
| PUBMED
27. Skeie GO, Mygland Å, Aarli Ja, Gilhus NE. Titin antibodies in patients with late onset myasthenia gravis: clinical correlations. Autoimmunity. 1995;20:99-104.
ISI
| PUBMED
28. Somnier F, Trojaburg W. Neurophysiological evaluation in myasthenia gravis: a comprehensive study of a complete patient population. Electroencephalogr Clin Neurophysiol. 1993;89:73-87.
FULL TEXT
|
ISI
| PUBMED
29. Keynes GK. Thymectomy for myasthenia gravis. Thorax. 1949;4:126-148.
30. Olanow CW, Lane RJM, Roses AD. Thymectomy in late-onset myasthenia gravis. Arch Neurol. 1982;39:82-83.
FREE FULL TEXT
31. Monden Y, Nakahara K, Fuji Y, et al. Myasthenia gravis in elderly patients. Ann Thorac Surg. 1985;39:433-436.
ABSTRACT
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED ARTICLE
Archives of Neurology Reader's Choice: Continuing Medical Education
Arch Neurol. 1999;56(1):129-131.
FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Increasing incidence of elderly onset patients with myasthenia gravis in a local area of Japan
Matsui et al.
J. Neurol. Neurosurg. Psychiatry 2009;80:1168-1171.
ABSTRACT
| FULL TEXT
Neurological care and risk of hospital mortality for patients with myasthenia gravis in England
Hill and Ben-Shlomo
J. Neurol. Neurosurg. Psychiatry 2008;79:421-425.
ABSTRACT
| FULL TEXT
Myasthenia gravis: a long term follow-up study of Swedish patients with specific reference to thymic histology
Tsinzerling et al.
J. Neurol. Neurosurg. Psychiatry 2007;78:1109-1112.
ABSTRACT
| FULL TEXT
Increasing incidence of late-onset anti-AChR antibody-seropositive myasthenia gravis
Somnier
Neurology 2005;65:928-930.
ABSTRACT
| FULL TEXT
A population based epidemiological study on myasthenia gravis in Estonia
Oopik et al.
J. Neurol. Neurosurg. Psychiatry 2003;74:1638-1643.
ABSTRACT
| FULL TEXT
Evidence of underdiagnosis of myasthenia gravis in older people
Vincent et al.
J. Neurol. Neurosurg. Psychiatry 2003;74:1105-1108.
ABSTRACT
| FULL TEXT
Do titin and cytokine antibodies in MG patients predict thymoma or thymoma recurrence?
Buckley et al.
Neurology 2001;57:1579-1582.
ABSTRACT
| FULL TEXT
Titin, Thymoma, and Myasthenia Gravis
Aarli
Arch Neurol 2001;58:869-870.
FULL TEXT
The Severity of Myasthenia Gravis Correlates With the Serum Concentration of Titin and Ryanodine Receptor Antibodies
Romi et al.
Arch Neurol 2000;57:1596-1600.
ABSTRACT
| FULL TEXT
Reply
Tsuchida et al.
Ann. Thorac. Surg. 2000;69:314-314.
FULL TEXT
|
